Ultragenyx Pharmaceutical (RARE) Assets (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Assets of $1.3 billion for Q1 2026, down 1.21% year-over-year from $1.3 billion in Q1 2025, and down 15.4% quarter-over-quarter from $1.5 billion in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Assets (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Assets for 14 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets fell 1.21% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (down 1.21% YoY), while the FY2025 annual figure was $1.5 billion, up 1.93% from the prior year.
- Assets slipped to $1.3 billion in Q1 2026 per RARE's latest filing, from $1.5 billion in the prior quarter.
- Across five years, Assets topped out at $1.6 billion in Q3 2022 and bottomed at $1.2 billion in Q3 2025.
- Historically, Assets has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2023.
- Annual changes were most pronounced in 2023 — Assets dropped 23.5% — and 2024, when it rose 24.25%.
- Ultragenyx Pharmaceutical's Assets stood at $1.5 billion in 2022, then retreated by 3.52% to $1.5 billion in 2023, then grew by 0.8% to $1.5 billion in 2024, then gained by 1.93% to $1.5 billion in 2025, then declined by 15.4% to $1.3 billion in 2026.
- Business Quant data shows RARE's Assets at $1.3 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 1.26 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.26 Bn |
| Mar 31, 2026 | 1.30 Bn |
| Dec 31, 2025 | 1.53 Bn |
| Sep 30, 2025 | 1.19 Bn |
| Jun 30, 2025 | 1.31 Bn |
| Mar 31, 2025 | 1.31 Bn |
| Dec 31, 2024 | 1.50 Bn |
| Sep 30, 2024 | 1.54 Bn |
| Jun 30, 2024 | 1.62 Bn |
| Mar 31, 2024 | 1.31 Bn |
| Dec 31, 2023 | 1.49 Bn |
| Sep 30, 2023 | 1.24 Bn |
| Jun 30, 2023 | 1.31 Bn |
| Mar 31, 2023 | 1.38 Bn |
| Dec 31, 2022 | 1.55 Bn |
| Sep 30, 2022 | 1.62 Bn |
| Jun 30, 2022 | 1.32 Bn |
| Mar 31, 2022 | 1.38 Bn |
| Dec 31, 2021 | 1.52 Bn |
| Sep 30, 2021 | 1.48 Bn |